JP Morgan Sec LLC Osmotica Pharma. - Osmotica Pharmaceuticals plc Amnd 8.3

RVL Pharmaceuticals

08/03/2021 15:03

RNS Number : 5335R

J.P. Morgan Securities LLC

08 March 2021

 

Ap19

 

 

   AMENDMENT

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Nameofpersondealing(Note1)
J.P. Morgan Securities LLC
Companydealtin
Osmotica Pharmaceuticals plc
Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate(Note2)
US$0.01 ordinary shares
Dateofdealing
04 March 2021

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long
Short
Number
(%)
Number
(%)
(1)Relevantsecurities
1,600,209 2.55
40,534 0.02
(2)Derivatives(otherthanoptions)
37 0.00
2,311 0.00
(3)Optionsandagreementstopurchase/sell
Total
1,600,246 2.55
42,845 0.02


 

 

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

Purchase/sale
Numberofrelevantsecurities
Priceperunit(USD)
(Note5)
Purchase(New Borrow)
Purchases
Purchases
Purchases
Purchases
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
Sales
54,400
110
285
680
11
100
50
168
11
110
139
680
162
100
100
11
N/A
3.4796 USD
3.4800 USD
3.5073 USD
3.6100 USD
3.4500 USD
3.4600 USD
3.4688 USD
3.4700 USD
3.4796 USD
3.4800 USD
3.5073 USD
3.5279 USD
3.5600 USD
3.5700 USD
3.6100 USD

 

 

(b)      Derivatives transactions (other than options transactions)

 

Productname,
e.g.CFD
Natureoftransaction
(Note6)
Numberofrelevantsecurities
(Note7)
Priceperunit
(USD)
(Note5)
Equity Swap
Long
Long
110
680
3.4796 USD
3.5073 USD

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Productname,
e.g.calloption
Writing,selling,purchasing,varyingetc.
Numberofsecurities towhichtheoptionrelates(Note7)
Exercise price
Type,e.g.American,Europeanetc.
Expiry date
Optionmoney paid/receivedperunit(Note5)


 

(ii)      Exercising

 

Productname,
e.g.calloption
Numberofsecurities
Exercisepriceper unit(Note5)


 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Natureoftransaction
(Note8)
Details
Priceperunit
(if applicable) (Note 5)


 

 

 

 

 

 

 

 

 

 

                       Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 

relevant securities to which any derivative referred to on this form is referenced. If none, this

should be stated.

 

     None

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            NO

 

Dateofdisclosure
08 March 2021
Contactname
Alwyn Basch
Telephonenumber
0207 742 7407
IfaconnectedEFM,nameofofferee/offerorwithwhichconnected
N/A
IfaconnectedEFM,statenatureofconnection(Note10)
N/A

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
ISEFLFESVDITIIL